Trimbow a fixed combination triple therapy for COPD, recently received a positive opinion from the FDA of Europe, Committee for Medicinal Products for Human Use (CHMP). Trimbow combines three ingredients, an Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium bromide (GB).
In a previous blog post, we discussed how many companies are developing these triple combination medications to treat COPD and potentially asthma.
Asthma is a multi-faceted disease that can be treated in a multitude of ways. With a triple combination medication such as Trimbow, three different disease processes could be targeted. For many years inhaled corticosteroids were used as the sole treatment of asthma, with the advent of Advair (a combined inhaled steroid and Long Acting Beta Agonist), many patients had improved relief of their asthma symptoms. Over the last few years, researchers have discovered that adding a long-acting muscarinic antagonist (LAMA) gives improved relief for many asthmatic patients, in addition to COPD patients (Chronic Obstructive Pulmonary Disease). For COPD patients, LAMA were the standard of care, but it has been found that these patients also can benefit from inhaled corticosteroids and long acting beta agonists.
For asthma, “one size does not fit all” for medications for all patients. Other asthmatic products used that help patients but not all of them are Singulair (montelukast) and biological medications such as Xolair, Nucala and Cinqair. Targeted asthma medication is becoming the new trend to help determine which subset of patients would benefit from certain medications.
There were 2 major studies that supported the use of Trimbow. The first one was called Trilogy, published in The Lancet that showed a fixed ICS/LABA/LAMA triple combination was superior than using a fixed ICS/LABA. The other study was called TRINITY and it demonstrated that the ICS/LABA/LAMA triple fixed dose combination therapy, developed by Chiesi was superior than the LAMA tioptropium. All of these studies have been for COPD, but Chiesi and other companies such as GSK, anticipate to getting the fixed triple combo meds approved for asthma as well.
The brand name Trimbow will be used in Europe, it is possible the name could be different in the United States when this medication is launched. A final decision by the European Commission is expected in the 3rd quarter of 2017.
Please check back with us for more information on Trimbow and other asthma information in the future.